New Data Strengthen Case For RemeGen’s Telitacicept In gMG

‘Highest’ MG-ADL Response Rate

 
• By Dexter Jie Yan

Results from a China Phase III trial show the potential of RemeGen's fusion protein telitacicept in generalized myasthenia gravis. But study design differences make direct comparisons with argenx's FcRn inhibitor Vyvgart challenging.

Concept of Myasthenia Gravis written on sticky notes isolated on Wooden Table.
RemeGen has shown telitacicept's potenial as a an alternative to FcRn Inhibitors In gMG. • Source: Shutterstock

More from Clinical Trials

More from Rare Diseases